COMMUNIQUÉS West-GlobeNewswire

Proteon Therapeutics to Present at the JMP Securities Life Sciences Conference June 21st
14/06/2018
WALTHAM, Mass., June 14, 2018 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney and vascular [...]
ContraVir Pharmaceuticals Announces the Approval of the IND and Initiation of the Clinical Development Program of CRV431 in the United States
14/06/2018
EDISON, N.J., June 14, 2018 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development and commercialization of therapeutic drugs for the treatment of [...]
AIT Therapeutics Reports Financial Results for Three Months Ended March 31, 2018
14/06/2018
Announced positive top-line data for Nitric Oxide in Bronchiolitis (NO-BRO) Pilot Study Presented data from its inhaled Nitric Oxide study in patients infected with mycobacterium abscessus complex (MABSC) at the 2018 [...]
Progressive Care Inc. Continues to See Strong Prescription Numbers and Overall Revenue in May 2018
14/06/2018
MIAMI, June 14, 2018 (GLOBE NEWSWIRE) -- Progressive Care Inc. (OTCQB:RXMD), a personalized healthcare services and technology company, today announced further growth year-over-year in both revenue and number of [...]
Natus Medical Board Announces Commitment to Governance Enhancements
14/06/2018
PLEASANTON, Calif., June 14, 2018 (GLOBE NEWSWIRE) -- The Board of Directors of Natus Medical Incorporated today announced that it commits to taking certain actions to strengthen the Company's corporate governance based [...]
Evelo Biosciences to Present at the JMP Securities 2018 Life Sciences Conference
14/06/2018
CAMBRIDGE, Mass., June 14, 2018 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company pioneering monoclonal microbials designed to act on the gut-body network for the [...]
K2M Group Holdings, Inc. Announces Pricing of Private Offering of $65.0 Million Aggregate Principal Amount of 3.00% Convertible Senior Notes due 2025
14/06/2018
LEESBURG, Va., June 14, 2018 (GLOBE NEWSWIRE) -- K2M Group Holdings, Inc. (Nasdaq:KTWO) (“K2M”) today announced the pricing of a private offering of $65.0 million aggregate principal amount of 3.00% Convertible Senior [...]
Arsanis Out-Licenses Preclinical Stage Klebsiella pneumoniae Monoclonal Antibodies from ASN300 Program
14/06/2018
Second recent transaction with Bravos Biosciences consolidates development of Arsanis gram-negative mAb candidates with global experts in anti-infective drug development WALTHAM, Mass. and VIENNA, Austria, June 14, 2018 [...]
Retrophin Announces Expansion of Intellectual Property Estate for Sparsentan with Newly Issued U.S. Patent
14/06/2018
SAN DIEGO, June 14, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced that the United States Patent and Trademark Office (USPTO) has issued a new patent covering the Company’s product candidate [...]
Epinephrine Nasal Spray in Development for Treatment of Anaphylaxis Shows Promise as Potential Alternative to Intramuscular Injection
14/06/2018
PHOENIX, June 14, 2018 (GLOBE NEWSWIRE) -- Allergy sufferers who experience anaphylaxis—an acute, life-threatening allergic reaction requiring urgent treatment—may soon have a new delivery option for receiving a timely [...]
Rhythm Pharmaceuticals Completes Pivotal Enrollment in Two Ongoing Phase 3 Clinical Trials Evaluating Setmelanotide in Rare Genetic Disorders of Obesity
14/06/2018
One-Year Data from Cohorts of 10 Enrolled Patients to Support Concurrent New Drug Application (NDA) Filings in POMC and LEPR Deficiency Obesity BOSTON, June 14, 2018 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. ( [...]
Kura Oncology to Present at JMP Securities Life Sciences Conference
14/06/2018
SAN DIEGO, June 14, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that Troy Wilson [...]
CytomX Announces Appointment of Lloyd A. Rowland Jr. as General Counsel
14/06/2018
Brings 25 Years of Biotechnology and Pharmaceutical Legal Leadership Experience SOUTH SAN FRANCISCO, Calif., June 14, 2018 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX) a clinical-stage oncology-focused [...]
Dragon Jade to Engage ICR, Inc. for Strategic Investor Relations Services
14/06/2018
HONG KONG, June 14, 2018 (GLOBE NEWSWIRE) -- Dragon Jade International Limited (“Dragon Jade” or “the Company”) (OTCQX:DGJI), a provider of premier medical products and services, today announced that it has retained ICR [...]
Aptose Enters Into License Agreement With CrystalGenomics to Acquire CG-806 Rights in China
14/06/2018
Aptose adds China territory to its global rights; CrystalGenomics to receive upfront payment and future payments SAN DIEGO and SEOUL, South Korea, June 14, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO [...]
Trillium Therapeutics Doses First Patient With TTI-622, Its Second Immune Checkpoint Inhibitor Targeting CD47
14/06/2018
TORONTO, June 14, 2018 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ:TRIL) (TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that [...]
New Research from NRC Health and MetroHealth: Patients Willing to Switch Providers for Ease
14/06/2018
The latest white paper from NRC Health, produced in partnership with The MetroHealth System of Cleveland, finds that excellent care is not enough to earn patient loyalty—patients desire effortless experiences LINCOLN, [...]
CellAegis Announces Completion of Patient Enrollment in UK Investigator Sponsored Clinical Trial using autoRIC® Device
14/06/2018
TORONTO, June 14, 2018 (GLOBE NEWSWIRE) -- CellAegis Devices Inc. (“CellAegis” or the “Company”), a commercial-stage medical device company advancing innovative, non-invasive, safe and cost-effective solutions for acute [...]
Stemline Therapeutics Announces Three ELZONRIS™ (tagraxofusp; SL-401) Clinical Presentations, Including an Oral Presentation, at the EHA Congress
14/06/2018
NEW YORK, June 14, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, announced that ELZONRIS TM (tagraxofusp; SL-401) [...]

Pages